# | Title | Journal | Year | Citations |
---|
1 | Robust enumeration of cell subsets from tissue expression profiles | Nature Methods | 2015 | 8,460 |
2 | Determining cell type abundance and expression from bulk tissues with digital cytometry | Nature Biotechnology | 2019 | 2,396 |
3 | Profiling Tumor Infiltrating Immune Cells with CIBERSORT | Methods in Molecular Biology | 2018 | 1,936 |
4 | An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage | Nature Medicine | 2014 | 1,771 |
5 | Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 943 |
6 | Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2020 | 848 |
7 | Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry | Annals of Oncology | 2019 | 842 |
8 | Integrated digital error suppression for improved detection of circulating tumor DNA | Nature Biotechnology | 2016 | 837 |
9 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes | American Journal of Human Genetics | 2019 | 711 |
10 | Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling | Cancer Discovery | 2017 | 701 |
11 | Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer | JAMA Oncology | 2020 | 696 |
12 | Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 672 |
13 | Revised FIGO staging for carcinoma of the cervix uteri | International Journal of Gynecology and Obstetrics | 2019 | 612 |
14 | Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue | JAMA Oncology | 2017 | 580 |
15 | Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2022 | 562 |
16 | Single-cell transcriptional diversity is a hallmark of developmental potential | Science | 2020 | 557 |
17 | Detecting circular RNAs: bioinformatic and experimental challenges | Nature Reviews Genetics | 2016 | 554 |
18 | Prostate Cancer, Version 1.2016 | Journal of the National Comprehensive Cancer Network: JNCCN | 2016 | 544 |
19 | Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial | Lancet Oncology, The | 2017 | 447 |
20 | Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses | Nature Medicine | 2016 | 437 |
21 | NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017 | Journal of the National Comprehensive Cancer Network: JNCCN | 2017 | 408 |
22 | Clinical lessons learned from the first leg of the CAR T cell journey | Nature Medicine | 2019 | 400 |
23 | Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 393 |
24 | Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy | Leukemia | 2019 | 385 |
25 | Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 385 |
26 | Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2020 | 383 |
27 | Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial | Lancet Oncology, The | 2019 | 366 |
28 | Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database | Genetics in Medicine | 2020 | 365 |
29 | Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element | Cell | 2018 | 362 |
30 | Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer | Cancer Epidemiology Biomarkers and Prevention | 2017 | 341 |
31 | Racial and Ethnic Disparities in Cancer Survival: The Contribution of Tumor, Sociodemographic, Institutional, and Neighborhood Characteristics | Journal of Clinical Oncology | 2018 | 330 |
32 | Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia | Nature Biotechnology | 2019 | 321 |
33 | NCCN Guidelines Insights: Breast Cancer, Version 1.2017 | Journal of the National Comprehensive Cancer Network: JNCCN | 2017 | 317 |
34 | Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 314 |
35 | NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020 | Journal of the National Comprehensive Cancer Network: JNCCN | 2020 | 314 |
36 | Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation | Proceedings of the National Academy of Sciences of the United States of America | 2015 | 307 |
37 | Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial | Journal of Hematology and Oncology | 2017 | 302 |
38 | Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 298 |
39 | EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes | Journal of Clinical Oncology | 2019 | 286 |
40 | NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020 | Journal of the National Comprehensive Cancer Network: JNCCN | 2020 | 284 |
41 | Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019 | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 281 |
42 | NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017 | Journal of the National Comprehensive Cancer Network: JNCCN | 2017 | 272 |
43 | Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing | Blood | 2015 | 270 |
44 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses | Nature Genetics | 2020 | 265 |
45 | Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction | Nature Genetics | 2021 | 264 |
46 | Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity‐modulated radiotherapy | Cancer | 2016 | 254 |
47 | Profiling Cell Type Abundance and Expression in Bulk Tissues with CIBERSORTx | Methods in Molecular Biology | 2020 | 249 |
48 | Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I | Haematologica | 2015 | 246 |
49 | Cognitive Training for Improving Executive Function in Chemotherapy-Treated Breast Cancer Survivors | Clinical Breast Cancer | 2013 | 237 |
50 | Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma | Journal of Immunotherapy | 2019 | 231 |